Primary membranous nephropathy in the era of autoantibodies and biological therapies

Abstract

Primary membranous nephropathy is an autoimmune kidney disease and the most common cause of nephrotic syndrome in adults. About 70%-80% of cases are caused by anti-PLA2R antibodies. Its association with anti-THSD7A antibodies and other autoantibodies has also been described. Recent pilot studies and clinical trials have shown that several biological agents targeting autoantibody-producing cells are effective in controlling the disease with an acceptable safety profile. In this narrative review, we update key concepts about the pathogenesis, autoantibody-based diagnosis, and kidney biopsy findings in primary membranous nephropathy. In addition, we propose a diagnostic and therapeutic algorithm, including guidance on monitoring the response to therapy. We compare the efficacy and safety of currently available treatments, including rituximab and new biological agents, and identify unmet clinical needs.

Keywords: Anti-CD20 treatment; Anti-PLA2R antibodies; Anticuerpos anti-PLA2R; Immunosuppressive therapy; Membranous nephropathy; Nefropatía membranosa primaria; Nephrotic syndrome; Síndrome nefrótico; Terapia inmunosupresora; Tratamiento anti-CD20.